---
title: "Tianjin Development’s Lisheng Pharma Unit Posts Strong 2025 Preliminary Profit Surge"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278456267.md"
description: "Tianjin Development Holdings announced that its subsidiary, Tianjin Lisheng Pharmaceutical, reported strong preliminary results for 2025. Revenue increased by 4.23% year-on-year to RMB1.39 billion, while net profit attributable to shareholders surged 126.72% to RMB418 million. The growth was driven by market expansion and stronger product sales. Despite a slight decline in net assets per share, the results highlight the company's significant stake in China's healthcare market."
datetime: "2026-03-09T22:37:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278456267.md)
  - [en](https://longbridge.com/en/news/278456267.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278456267.md)
---

# Tianjin Development’s Lisheng Pharma Unit Posts Strong 2025 Preliminary Profit Surge

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Tianjin Development Holdings ( (HK:0882) ) just unveiled an announcement.

Tianjin Development Holdings has disclosed that its indirect subsidiary Tianjin Lisheng Pharmaceutical reported solid preliminary results for 2025, underscoring the growing contribution of its pharmaceutical operations. The company maintains a significant minority stake of just over one‑third in Lisheng, reinforcing its exposure to China’s healthcare and drug markets.

Lisheng Pharmaceutical’s unaudited 2025 figures show revenue rising 4.23 percent year on year to RMB1.39 billion, with operating profit more than doubling. Net profit attributable to shareholders surged 126.72 percent to RMB418 million, boosted by market expansion, stronger product sales and dividends from an equity instrument, though net assets per share edged lower as total assets and equity declined slightly.

**More about Tianjin Development Holdings**

Tianjin Development Holdings is a Hong Kong‑incorporated conglomerate with interests including pharmaceuticals through its indirect, non‑wholly owned subsidiary Tianjin Lisheng Pharmaceutical, in which it holds about 34.12 percent. Lisheng Pharmaceutical operates in China’s pharmaceutical sector, generating revenue from the sale of medical products and related activities, and is listed on the Shenzhen Stock Exchange under stock code 002393.

**Average Trading Volume:** 570,194

**Current Market Cap:** HK$2.85B

For a thorough assessment of 0882 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [00882.HK](https://longbridge.com/en/quote/00882.HK.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [002393.CN](https://longbridge.com/en/quote/002393.CN.md)

## Related News & Research

- [LabWare and Phizzle Partnership to Eliminate Manual Instrument Data Transfer in Pharmaceutical Cleanroom Labs](https://longbridge.com/en/news/282085838.md)
- [China to Let Firms Set New Drug Prices Based on Clinical Value, R&D Costs and Risks](https://longbridge.com/en/news/282939130.md)
- [TransThera Sciences Launches Discounted HK$290 Million H-Share Placement](https://longbridge.com/en/news/282767094.md)
- [Cutia Therapeutics’ Botox Rival Meets Phase III Goals in China](https://longbridge.com/en/news/282464943.md)
- [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md)